Hanmi Pharm Signs Supply Contract for 3 Cardiovascular/Respiratory Drugs in Philippines and Malaysia (Approx. 52.7 Billion KRW)

Contract value: 52,738,853,215 KRW (3.4% of 2025 consolidated revenue)
Subject: 3 cardiovascular/respiratory drugs, Counterparty: Organon International GmbH
Territory: Philippines and Malaysia, Contract period: 10 years from local launch (expected 2026-2036)
Terms: Includes license fee of USD 1,075,000 and estimated 10-year sales of USD 34,088,924
Unapproved products may be excluded from supply scope if local approvals fail

ADVERTISEMENT (250px+)